21 light-orange Marlissa tablets, each containing 0.15 mg of levonorgestrel USP, (-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one, a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol USP, (19-nor-17α-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and 7 pink inert tablets. The inactive ingredients present in 21 light orange active tablets are FD&C Yellow 6, lactose monohydrate, magnesium stearate, polacrilin potassium, microcrystalline cellulose, povidone and talc. The inactive ingredients present in the 7 pink inert tablets are D&C Red 30, lactose monohydrate, magnesium stearate, polacrilin potassium, microcrystalline cellulose, povidone and talc.
Marlissa is a combination medicine that consists of two generic medicines. These are the progestin hormone, levonorgestrel and an estrogen hormone, ethinyl estradiol. Marlissa presents as a round, orange tablet and comes as a 28-day pack dose. It is classified as a hormonal drug and is administered orally or by mouth.